PRDO vs UTI: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

PRDO is the larger of the two ($1.72B market cap): the incumbent the market prices for continued execution (8.41x forward earnings, beta 0.75). UTI is the smaller challenger ($986.27M), actually pricier on forward earnings (19.25x): more room to run, but more to prove. If you believe in growth, UTI fits: analysts expect its revenue to rise 10% next year, against 2% for PRDO. If you believe in paying less for profit, PRDO fits: it trades at 8.41x forward earnings, against 19.25x for UTI.

PRDO vs UTI: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricPRDOUTIWhat it tells you
Market cap$1.72B$986.27MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E8.4119.25Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E9.7029.83Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.751.21Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range12% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.642.86How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: PRDO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how PRDO and UTI affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PRDO and UTI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PRDO and UTI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Perdoceo Education Corporation (PRDO) do?

Perdoceo Education Corporation (Nasdaq: PRDO) is the Schaumburg, Illinois company that used to trade as Career Education Corporation; it took the Perdoceo name in December 2019 after shedding its campus-heavy culinary and art-school businesses. What remains is three accredited postsecondary institutions. Colorado Technical University is the largest, at ~31,870 students as of September 30, 2026 (down ~0.5%) and about two thirds of total enrolment, with roughly 98% of those students fully online. The American InterContinental University System adds ~10,830 students, up ~7.5%, also almost entirely online. The third piece, the University of St. Augustine for Health Sciences, is the odd one out and the interesting one: a campus-based graduate school in physical therapy, occupational therapy, speech language therapy and nursing, ~4,560 students, up ~3.2%, with revenue growing near 10%. Total enrolment across all three was ~47,260, up ~1.6% year over year.

Full PRDO guide

What does Universal Technical Institute (UTI) do?

Universal Technical Institute, Inc. (NYSE: UTI) runs postsecondary vocational schools across two reportable segments. The legacy UTI segment trains students in automotive, diesel, motorcycle, marine, welding, CNC and related skilled trades, while the Concorde Career Colleges segment (acquired in 2022) offers allied health, dental, nursing, patient-care and diagnostic programs. The company generates revenue primarily from student tuition, much of it funded through federal Title IV financial aid, and it has been growing student starts and average full-time enrollment at both segments.

Full UTI guide

PRDO vs UTI: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • PRDO drivers: St. Augustine is the segment carrying the growth; Earnings growth is being manufactured below the revenue line.
  • UTI drivers: Skilled-trades demand tailwind; Concorde and healthcare diversification.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is regulatory concentration more than competition: approximately ~$615 million of Title IV cash receipts in 2025 against ~$846.1 million of revenue means a change in federal aid rules, eligibility, or appropriations flows almost directly into the P&L, and management lists a government shutdown or Department of Education restructuring among its own guidance assumptions. For UTI, uTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business.

PRDO or UTI: which should you pick?

If the story you believe is PRDO's (St. Augustine is the segment carrying the growth), PRDO is the more direct way to own it; if it is UTI's (Skilled-trades demand tailwind), UTI is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PRDO and UTI guides.

PRDO vs UTI: the full fundamentals

PRDO. The trailing multiple looks unusually low until the cash is stripped out, at which point enterprise value is about 4.3 times trailing EBITDA. That is the market applying a persistent discount to Title IV dependence and litigation overhang, and the fall to ~$27.77 by November 20, 2026 widened it. Two things to check against the filings: part of 2026 EPS growth came from a lower effective tax rate in the first half (~20.6% versus ~24.9%), and the South University purchase would reduce the cash cushion by roughly a fifth when it closes.

UTI. The fiscal 2027 outlook reset the earnings path again: at ~$18.17 the stock trades near 30 times trailing EPS of ~$0.60, but guided fiscal 2027 EPS of $0 to $0.09 makes a forward P/E close to meaningless, so the market is valuing UTI on revenue (~1.1x trailing sales) and on adjusted EBITDA guided at $100 to $106 million. The market value of roughly ~$1.0 billion is well under half its mid-2026 level. The mean analyst target of about ~$32 from six analysts still sits far above the price, which shows how wide the gap is between the 2029 plan and what the market is willing to pay for it today.

Headline figures (approximate, November 2026): PRDO shows revenue (ttm) ~$863M, up ~1.9% year over year in Q3 2026, net income / diluted eps (ttm) ~$182M and ~$2.86; profit margin ~21.1%, operating margin ~24.9%, latest quarter (q3 2026) Adjusted EPS ~$0.77 vs ~$0.74 estimate; revenue ~$215.9M, market cap and p/e ~$1.72B at ~$27.77 per share; ~9.7x trailing, ~8.4x forward earnings; UTI shows revenue (fy2026) ~$897M, +~7.4% YoY, revenue (fq4 2026) ~$235.9M, +~6% YoY, net income (fy2026) ~$33.6M (~$0.60 per share), adjusted ebitda (fy2026) ~$102M after ~$34.6M of growth investment.

The bottom line: PRDO vs UTI

PRDO and UTI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined PRDO and UTI exposure against your real portfolio. It is not an investment adviser.

Wondering how PRDO or UTI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Perdoceo Education Corporation

Ask Walnut's AI anything about PRDO and see how it fits what you own.

FAQ

What is the difference between PRDO and UTI?

+

Perdoceo Education Corporation (Nasdaq: PRDO) is the Schaumburg, Illinois company that used to trade as Career Education Corporation; it took the Perdoceo name in December 2019 after shedding its campus-heavy culinary and art-school businesses. Universal Technical Institute, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is PRDO or UTI the better stock?

+

Neither is universally better. PRDO is the larger incumbent; UTI is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, PRDO or UTI?

+

On forward P/E (as of November 2026), PRDO trades at 8.41x and UTI at 19.25x, so PRDO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both PRDO and UTI?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of PRDO vs UTI?

+

PRDO: The dominant risk is regulatory concentration more than competition: approximately ~$615 million of Title IV cash receipts in 2025 against ~$846.1 million of revenue means a change in federal aid rules, eligibility, or appropriations flows almost directly into the P&L, and management lists a government shutdown or Department of Education restructuring among its own guidance assumptions. All three institutions were preliminarily in compliance with the 90/10 rule for 2025 and improved versus the prior year, but the calculation methodology is unsettled and the penalty for two consecutive years above the threshold is loss of Title IV eligibility for at least two fiscal years. The elimination of Grad PLUS for new borrowers from July 1, 2026, with new caps on graduate Direct Unsubsidized borrowing, lands squarely on USAHS, the one segment carrying the growth, and the company's assumption that displaced students find private lending is untested. Two False Claims Act qui tam suits brought by former Colorado Technical University employees are live in the District of Colorado, both seeking treble damages, with the Department of Justice having declined to intervene in each; the company has recognised no liability and cannot estimate a range, and higher legal fees again held back CTU segment operating income in the third quarter. Finally, the core online universities are barely growing, marketing is lead-driven, and Perdoceo itself flags increased use of AI assistants in place of search engines as a factor that could disrupt how it reaches prospective students. The South University acquisition adds integration and approval risk: it needs regulatory and accreditor sign-off, South has changed control four times in under a decade, and converting it from nonprofit to for-profit status brings it under the 90/10 rule and the same Title IV scrutiny as the rest of the group. The stock's ~18% drop in the month to November 20, 2026, after a quarter that beat estimates, shows how quickly sentiment on the sector can swing. UTI: UTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business. Near-term profitability has already collapsed on expansion spending: fiscal 2026 net income of ~$33.6 million was down from ~$63 million in fiscal 2025, and fiscal 2027 net income is guided to just $0 to $5 million, so the earnings base the market can value is close to zero for a year. The for-profit education sector carries a history of regulatory scrutiny and reputational risk. Rising labor and real-estate costs can pressure margins, and an economic downturn can cut both ways on enrollment. Admissions execution has now disappointed in consecutive quarters, with fourth-quarter starts up only ~3.3%, and a mix shift toward shorter, lower-priced programs could weigh on revenue per student even if starts recover. New campuses need regulatory approval to open on schedule. Debt of ~$325 million against ~$171 million of cash, plus the revolver and a much larger capex plan, adds balance-sheet exposure that a debt-light company would not carry. Analysts have reset their targets after the report (Truist to $26 from $38, B. Riley to $39 from $45), and the stock fell about 17% over the month to November 20, 2026.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell PRDO or UTI; figures are approximate and dated (as of November 2026). Verify current data before investing.